The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Target Advancement Program, 2016Alpha-Synuclein Aggregates as an Inducer of Glial Senescence: Potential Role in Parkinson's Disease
Study Rationale:
Cellular senescence (deterioration) is a critical factor of biological aging that occurs in almost all peripheral tissues but little is known about its... -
Therapeutic Pipeline Program, 2016Highly Selective M1 Muscarinic Receptor Positive Allosteric Modulators for the Treatment of Parkinson's Dementia
Study Rationale:
Up to 80% of individuals with Parkinson’s develop Parkinson’s disease dementia (PDD), which is characterized by a progressive loss of memory and a decline... -
Therapeutic Pipeline Program, 2015Alpha4Beta2 Nicotinic Agonist for Treatment of L-Dopa Refractory Gait and Balance Disorders in Parkinson Disease
Study Rationale:
Gait and balance problems, particularly falls, are common and disabling symptoms in Parkinson disease (PD), and do not improve markedly with existing treatments. Studies have indicated... -
Target Advancement Program, 2016Genetic Modulation of LAMP-2A in PD Models
Study Rationale:
Brain cells use surveillance mechanisms to get rid of toxic proteins, such as mutant alpha-synuclein, that otherwise would accumulate and kill them. We have... -
Target Advancement Program, 2016Mechanism of TFEB Dysfunction by GBA1 Mutation in Human iPSC-derived Dopaminergic Neurons
Study Rationale:
People who have mutations in the GBA1 gene have a higher chance of developing Parkinson's disease (PD) but it is unclear why. We found that GBA1 mutations affect the cellular ability... -
Target Validation, 2015Validating the Neuroprotective Enzyme ACMSD as a Novel Therapeutic Target in Parkinson's Disease by Viral Vector-Mediated Overexpression
Study Rationale:
A number of genetic studies have linked variation in the enzyme aminocarboxy-muconate semialdehyde decarboxylase (ACMSD) with a risk for Parkinson’s...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.